Damora Therapeutics, Inc. Common Stock (DMRA) – What Are Brokerages Thinking About This Stock?

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have received an average recommendation of “Buy” from the twelve analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and three have issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $46.38.

A number of research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Wall Street Zen upgraded shares of Damora Therapeutics, Inc. Common Stock from a “sell” rating to a “hold” rating in a research report on Sunday, November 8th. Wedbush restated an “outperform” rating and issued a $40.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, September 29th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Finally, TD Cowen upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, August 24th.

Insider Activity at Damora Therapeutics, Inc. Common Stock

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett bought 12,500 shares of the business’s stock in a transaction that occurred on Friday, September 25th. The shares were bought at an average price of $20.23 per share, for a total transaction of $252,875.00. Following the transaction, the chief executive officer directly owned 512,500 shares in the company, valued at approximately $10,367,875. This trade represents a 2.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

A number of institutional investors and hedge funds have recently modified their holdings of DMRA. Braidwell LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $42,146,000. Seven Fleet Capital Management LP bought a new stake in Damora Therapeutics, Inc. Common Stock in the second quarter valued at $7,398,000. Squarepoint Ops LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the second quarter valued at about $303,000. Finally, Arizona State Retirement System acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $260,000. 14.20% of the stock is currently owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Trading Down 2.0%

NASDAQ DMRA opened at $21.60 on Monday. The business’s 50-day moving average price is $22.19 and its two-hundred day moving average price is $25.61. Damora Therapeutics, Inc. Common Stock has a 12 month low of $15.76 and a 12 month high of $38.33. The firm has a market capitalization of $1.34 billion, a PE ratio of -15.32 and a beta of 1.52.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.12. As a group, analysts forecast that Damora Therapeutics, Inc. Common Stock will post -2.09 earnings per share for the current fiscal year.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.